Filana Therapeutics, Inc. SEC filings FLNA

Filana Therapeutics, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to Nov 9, 2006. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
10-Q Quarterly report Nov 5, 2026 Sep 30, 2026
10-Q Quarterly report Jul 29, 2026 Jun 30, 2026
10-Q Quarterly report May 7, 2026 Mar 31, 2026
10-Q Quarterly report Nov 12, 2025 Sep 30, 2025
10-Q Quarterly report Aug 14, 2025 Jun 30, 2025
10-Q Quarterly report May 8, 2025 Mar 31, 2025
10-Q Quarterly report Nov 7, 2024 Sep 30, 2024
10-Q Quarterly report Aug 8, 2024 Jun 30, 2024
10-Q Quarterly report May 10, 2024 Mar 31, 2024
10-Q Quarterly report Nov 7, 2023 Sep 30, 2023
10-Q Quarterly report Aug 3, 2023 Jun 30, 2023
10-Q Quarterly report May 1, 2023 Mar 31, 2023
10-Q Quarterly report Nov 7, 2022 Sep 30, 2022
10-Q Quarterly report Aug 4, 2022 Jun 30, 2022
10-Q Quarterly report May 5, 2022 Mar 31, 2022
10-Q Quarterly report Nov 15, 2021 Sep 30, 2021
10-Q Quarterly report Aug 4, 2021 Jun 30, 2021
10-Q Quarterly report Apr 29, 2021 Mar 31, 2021
10-Q Quarterly report Nov 9, 2020 Sep 30, 2020
10-Q Quarterly report Aug 12, 2020 Jun 30, 2020
10-Q Quarterly report May 6, 2020 Mar 31, 2020
10-Q Quarterly report Oct 29, 2019 Sep 30, 2019
10-Q Quarterly report Aug 12, 2019 Jun 30, 2019
10-Q Quarterly report May 2, 2019 Mar 31, 2019
10-Q Quarterly report Oct 30, 2018 Sep 30, 2018
10-Q Quarterly report Jul 26, 2018 Jun 30, 2018
10-Q Quarterly report May 9, 2018 Mar 31, 2018
10-Q Quarterly report Nov 1, 2017 Sep 30, 2017
10-Q Quarterly report Aug 9, 2017 Jun 30, 2017
10-Q Quarterly report Apr 26, 2017 Mar 31, 2017
10-Q Quarterly report Oct 26, 2016 Sep 30, 2016
10-Q Quarterly report Jul 19, 2016 Jun 30, 2016
10-Q Quarterly report May 5, 2016 Mar 31, 2016
10-Q Quarterly report Nov 9, 2015 Sep 30, 2015
10-Q Quarterly report Jul 23, 2015 Jun 30, 2015
10-Q Quarterly report May 8, 2015 Mar 31, 2015
10-Q Quarterly report Nov 5, 2014 Sep 30, 2014
10-Q Quarterly report Aug 6, 2014 Jun 30, 2014
10-Q Quarterly report May 7, 2014 Mar 31, 2014
10-Q Quarterly report Nov 1, 2013 Sep 30, 2013
10-Q Quarterly report Aug 1, 2013 Jun 30, 2013
10-Q Quarterly report Apr 24, 2013 Mar 31, 2013
10-Q Quarterly report Nov 9, 2012 Sep 30, 2012
10-Q Quarterly report Aug 2, 2012 Jun 30, 2012
10-Q Quarterly report May 8, 2012 Mar 31, 2012
10-Q Quarterly report Nov 3, 2011 Sep 30, 2011
10-Q Quarterly report Aug 4, 2011 Jun 30, 2011
10-Q Quarterly report Apr 27, 2011 Mar 31, 2011
10-Q Quarterly report Oct 29, 2010 Sep 30, 2010
10-Q Quarterly report Jul 29, 2010 Jun 30, 2010
10-Q Quarterly report Apr 30, 2010 Mar 31, 2010
10-Q Quarterly report Oct 30, 2009 Sep 30, 2009
10-Q Quarterly report Aug 5, 2009 Jun 30, 2009
10-Q Quarterly report May 6, 2009 Mar 31, 2009
10-Q Quarterly report Oct 29, 2008 Sep 30, 2008
10-Q Quarterly report Jul 30, 2008 Jun 30, 2008
10-Q Quarterly report May 7, 2008 Mar 31, 2008
10-Q Quarterly report Nov 2, 2007 Sep 30, 2007
10-Q Quarterly report Aug 9, 2007 Jun 30, 2007
10-Q Quarterly report May 4, 2007 Mar 31, 2007

Showing 60 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
FLNA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Austin, TX
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1069530
Former names
CASSAVA SCIENCES INC (until Feb 19, 2026); PAIN THERAPEUTICS INC (until Mar 25, 2019)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.